MYMX Stock Overview
Mymetics Corporation engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Mymetics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.01 |
| 52 Week High | US$56.60 |
| 52 Week Low | US$0.01 |
| Beta | 1.65 |
| 1 Month Change | 0% |
| 3 Month Change | -96.16% |
| 1 Year Change | -99.94% |
| 3 Year Change | -100.00% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| MYMX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.0% | 1.2% |
| 1Y | -99.9% | 0.7% | 24.9% |
Return vs Industry: MYMX underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: MYMX underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| MYMX volatility | |
|---|---|
| MYMX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MYMX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MYMX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 2 | n/a | www.mymetics.com |
Mymetics Corporation engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company’s product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, malaria, and chikungunya. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative and the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines.
Mymetics Corporation Fundamentals Summary
| MYMX fundamental statistics | |
|---|---|
| Market cap | US$1.52k |
| Earnings (TTM) | -US$12.38m |
| Revenue (TTM) | US$570.42k |
0.0x
P/S Ratio0.0x
P/E RatioIs MYMX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYMX income statement (TTM) | |
|---|---|
| Revenue | €533.00k |
| Cost of Revenue | €758.00k |
| Gross Profit | -€225.00k |
| Other Expenses | €11.34m |
| Earnings | -€11.57m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -76.16 |
| Gross Margin | -42.21% |
| Net Profit Margin | -2,170.17% |
| Debt/Equity Ratio | -99.4% |
How did MYMX perform over the long term?
See historical performance and comparison